More Like this

1. Review of COVID-19 Antibody Therapies

   https://doi.org/10.1146/annurev-biophys-062920-063711  

   Chen, Jiahui; Gao, Kaifu; Wang, Rui; Nguyen, Duc Duy; Wei, Guo-Wei (May 2021, Annual Review of Biophysics)

   null (Ed.)

   In the global health emergency caused by coronavirus disease 2019 (COVID-19), efficient and specific therapies are urgently needed. Compared with traditional small-molecular drugs, antibody therapies are relatively easy to develop; they are as specific as vaccines in targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and they have thus attracted much attention in the past few months. This article reviews seven existing antibodies for neutralizing SARS-CoV-2 with 3D structures deposited in the Protein Data Bank (PDB). Five 3D antibody structures associated with the SARS-CoV spike (S) protein are also evaluated for their potential in neutralizing SARS-CoV-2. The interactions of these antibodies with the S protein receptor-binding domain (RBD) are compared with those between angiotensin-converting enzyme 2 and RBD complexes. Due to the orders of magnitude in the discrepancies of experimental binding affinities, we introduce topological data analysis, a variety of network models, and deep learning to analyze the binding strength and therapeutic potential of the 14 antibody–antigen complexes. The current COVID-19 antibody clinical trials, which are not limited to the S protein target, are also reviewed. 

   more » « less
2. Creation of monoclonal antibody expressing CHO cell lines grown with sodium butyrate and characterization of resulting antibody glycosylation

   https://doi.org/10.1016/bs.mie.2021.06.039  

   Nmagu, Douglas; Singh, Sumit K.; Lee, Kelvin H. (October 2021, Methods in enzymology)

   Chinese hamster ovary (CHO) cells are the primary mammalian cell lines utilized to produce monoclonal antibodies (mAbs). The upsurge in biosimilar development and the proven health benefits of mAb treatments reinforces the need for innovative methods to generate robust CHO clones and enhance production, while maintaining desired product quality attributes. Among various product titer-enhancing approaches, the use of histone deacetylase inhibitors (HDACis) such as sodium butyrate (NaBu) has yielded promising results. The titer-enhancing effect of HDACi treatment has generally been observed in lower producer cell lines but those studies are typically done on individual clones. Here, we describe a cell line development (CLD) platform approach for creating clones with varying productivities. We then describe a method for selecting an optimal NaBu concentration to evaluate potential titer-enhancing capabilities in a fed-batch study. Finally, a method for purifying the mAb using protein A chromatography, followed by glycosylation analysis using mass spectrometry, is described. The proposed workflow can be applied for a robust CLD process optimization to generate robust clones, enhance product expression, and improve product quality attributes. 

   more » « less
3. Progress toward improved understanding of antibody maturation

   https://doi.org/10.1016/j.sbi.2020.11.008  

   Vajda, Sandor; Porter, Kathryn A; Kozakov, Dima (April 2021, Current Opinion in Structural Biology)

   null (Ed.)
4. Antibody-Mediated Immobilization of Virions in Mucus

   https://doi.org/10.1007/s11538-019-00653-6  

   Jensen, Melanie A.; Wang, Ying-Ying; Lai, Samuel K.; Forest, M. Gregory; McKinley, Scott A. (October 2019, Bulletin of Mathematical Biology)
5. Antibody nanocarriers for cancer management

   https://doi.org/10.1016/j.cobme.2021.100295  

   Dang, Megan N.; Hoover, Elise C.; Scully, Mackenzie A.; Sterin, Eric H.; Day, Emily S. (September 2021, Current Opinion in Biomedical Engineering)